These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 29169525

  • 1. Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib.
    Nakanishi Y, Masuda S, Iida Y, Takahashi N, Hashimoto S.
    J Thorac Oncol; 2017 Dec; 12(12):e202-e204. PubMed ID: 29169525
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.
    Sehgal K, Peters MLB, VanderLaan PA, Rangachari D, Kobayashi SS, Costa DB.
    J Thorac Oncol; 2019 Jan; 14(1):e1-e3. PubMed ID: 29981924
    [No Abstract] [Full Text] [Related]

  • 9. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T.
    Lancet; 2017 Jul 01; 390(10089):29-39. PubMed ID: 28501140
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
    Ou SH, Milliken JC, Azada MC, Miller VA, Ali SM, Klempner SJ.
    Lung Cancer; 2016 Jan 01; 91():70-2. PubMed ID: 26464158
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Safety and Efficacy of Alectinib in a Patient With Advanced NSCLC Undergoing Hemodialysis.
    Suzuki S, Haratani K, Takahama T, Watanabe S, Takegawa N, Hayashi H, Takeda M, Yonesaka K, Nakagawa K.
    J Thorac Oncol; 2019 Mar 01; 14(3):e50-e52. PubMed ID: 30782383
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
    Yoshida T, Hida T, Yatabe Y.
    Anticancer Drugs; 2016 Jul 01; 27(6):573-5. PubMed ID: 26938871
    [Abstract] [Full Text] [Related]

  • 17. Second- and third-generation ALK inhibitors for non-small cell lung cancer.
    Wu J, Savooji J, Liu D.
    J Hematol Oncol; 2016 Mar 08; 9():19. PubMed ID: 26951079
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Discovery and development of alectinib hydrochloride (ALECENSAR capsule 20 mg and 40 mg)
].
    Yoshimura Y, Sakamoto H, Tanaka T, Inagaki N, Uzu M.
    Nihon Yakurigaku Zasshi; 2015 Jun 08; 145(6):318-24. PubMed ID: 26063155
    [No Abstract] [Full Text] [Related]

  • 20. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
    Gadgeel SM, Gandhi L, Riely GJ, Chiappori AA, West HL, Azada MC, Morcos PN, Lee RM, Garcia L, Yu L, Boisserie F, Di Laurenzio L, Golding S, Sato J, Yokoyama S, Tanaka T, Ou SH.
    Lancet Oncol; 2014 Sep 08; 15(10):1119-28. PubMed ID: 25153538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.